PDS Biotechnology Corporation Revenue and Competitors
Estimated Revenue & Valuation
- PDS Biotechnology Corporation's estimated annual revenue is currently $2.6M per year.
- PDS Biotechnology Corporation's estimated revenue per employee is $77,500
- PDS Biotechnology Corporation's total funding is $32M.
Employee Data
- PDS Biotechnology Corporation has 33 Employees.
- PDS Biotechnology Corporation grew their employee count by 3% last year.
PDS Biotechnology Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | SVP General Counsel | Reveal Email/Phone |
3 | VP Quality | Reveal Email/Phone |
4 | Head Human Resources & Facilities Administration | Reveal Email/Phone |
5 | Head Clinical Operations, (Sr. VP) | Reveal Email/Phone |
6 | VP, Legal Counsel and Assistant Secretary | Reveal Email/Phone |
7 | VP Commercial Development | Reveal Email/Phone |
8 | SVP, Business Development | Reveal Email/Phone |
9 | VP, Medical Affairs | Reveal Email/Phone |
10 | Senior Director, Technical Operations | Reveal Email/Phone |
PDS Biotechnology Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is PDS Biotechnology Corporation?
PDS Biotechnology Corporation is a biopharmaceutical company pioneering the development of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases.PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, cervical cancer, anal cancer, prostate cancer, breast cancer and other cancers. PDS Biotechnology’s lead product candidate PDS0101 demonstrated strong induction of the expected immune responses (e.g. antigen-specific CD8+ T-cell responses) without any observed dose-limiting toxicities in a completed Phase 1/2a clinical trial.
keywords:N/A
$32M
Total Funding
33
Number of Employees
$2.6M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
PDS Biotechnology Corporation News
PDS Biotechnology (NASDAQ:PDSB) said that on April 18 it received $1.2M ... profitable New Jersey corporation as the company participated in...
FLORHAM PARK, N.J., April 08, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company...
FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company...
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS to License Novel Proteins for Flu Vaccine PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine London, UK - 01 November 2021- NetScientific plc (AIM ...
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer Florham Park, NJ, October 4, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer t ...
Other Companies in Princeton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.6M | 33 | 3% | N/A |
#2 | $4.8M | 33 | -13% | N/A |
#3 | $3.5M | 33 | 6% | N/A |
#4 | $4.8M | 33 | 0% | N/A |
#5 | $7.3M | 34 | -3% | N/A |